Detalles de la búsqueda
1.
Utility of the frailty score for predicting prognosis and individualizing treatment intensity in elderly patients with diffuse large B cell lymphoma.
Ann Hematol
; 102(6): 1485-1500, 2023 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-37115298
2.
[Polatuzumab vedotin, bendamustine, and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma, including the outcome as a bridging treatment to CAR-T cell therapy or allogeneic hematopoietic stem cell transplant].
Rinsho Ketsueki
; 64(7): 586-595, 2023.
Artículo
en Japonés
| MEDLINE | ID: mdl-37544717
3.
[Tisagenlecleucel for relapsed/refractory diffuse large B-cell lymphoma: real-world data from single institute experience].
Rinsho Ketsueki
; 63(10): 1363-1372, 2022.
Artículo
en Japonés
| MEDLINE | ID: mdl-36351641
4.
Hemoglobin-platelet index as a prognostic factor in patients with peripheral T-cell lymphoma.
EJHaem
; 4(3): 656-666, 2023 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-37601871
5.
Clinical outcomes in transplant-eligible patients with relapsed or refractory diffuse large B-cell lymphoma after second-line salvage chemotherapy: A retrospective study.
Cancer Med
; 12(17): 17808-17821, 2023 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-37635630
Resultados
1 -
5
de 5
1
Próxima >
>>